|
Gene: TMPO |
Gene summary for TMPO |
Gene summary. |
Gene information | Species | Human | Gene symbol | TMPO | Gene ID | 7112 |
Gene name | thymopoietin | |
Gene Alias | CMD1T | |
Cytomap | 12q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000785 | UniProtAcc | A0A024RBE7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7112 | TMPO | LZE2T | Human | Esophagus | ESCC | 3.81e-03 | 8.23e-01 | 0.082 |
7112 | TMPO | LZE7T | Human | Esophagus | ESCC | 2.13e-06 | 6.92e-01 | 0.0667 |
7112 | TMPO | LZE8T | Human | Esophagus | ESCC | 6.50e-04 | 1.02e-01 | 0.067 |
7112 | TMPO | LZE22T | Human | Esophagus | ESCC | 5.41e-05 | 3.72e-01 | 0.068 |
7112 | TMPO | LZE24T | Human | Esophagus | ESCC | 4.44e-16 | 5.22e-01 | 0.0596 |
7112 | TMPO | LZE21T | Human | Esophagus | ESCC | 2.15e-02 | 4.05e-01 | 0.0655 |
7112 | TMPO | LZE6T | Human | Esophagus | ESCC | 2.05e-03 | 4.37e-01 | 0.0845 |
7112 | TMPO | P1T-E | Human | Esophagus | ESCC | 6.21e-04 | 4.28e-01 | 0.0875 |
7112 | TMPO | P2T-E | Human | Esophagus | ESCC | 1.62e-78 | 1.81e+00 | 0.1177 |
7112 | TMPO | P4T-E | Human | Esophagus | ESCC | 1.29e-26 | 1.07e+00 | 0.1323 |
7112 | TMPO | P5T-E | Human | Esophagus | ESCC | 2.59e-22 | 6.87e-01 | 0.1327 |
7112 | TMPO | P8T-E | Human | Esophagus | ESCC | 2.48e-24 | 6.32e-01 | 0.0889 |
7112 | TMPO | P10T-E | Human | Esophagus | ESCC | 1.41e-19 | 5.27e-01 | 0.116 |
7112 | TMPO | P11T-E | Human | Esophagus | ESCC | 1.92e-07 | 5.10e-01 | 0.1426 |
7112 | TMPO | P12T-E | Human | Esophagus | ESCC | 1.44e-15 | 3.69e-01 | 0.1122 |
7112 | TMPO | P15T-E | Human | Esophagus | ESCC | 1.84e-15 | 4.87e-01 | 0.1149 |
7112 | TMPO | P16T-E | Human | Esophagus | ESCC | 2.12e-24 | 6.55e-01 | 0.1153 |
7112 | TMPO | P17T-E | Human | Esophagus | ESCC | 1.05e-08 | 5.03e-01 | 0.1278 |
7112 | TMPO | P19T-E | Human | Esophagus | ESCC | 1.22e-03 | 7.57e-01 | 0.1662 |
7112 | TMPO | P20T-E | Human | Esophagus | ESCC | 1.75e-12 | 4.05e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMPO | SNV | Missense_Mutation | novel | c.622N>A | p.Glu208Lys | p.E208K | P42166 | protein_coding | deleterious_low_confidence(0.01) | benign(0.321) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
TMPO | SNV | Missense_Mutation | c.508N>C | p.Glu170Gln | p.E170Q | P42166 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.94) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
TMPO | SNV | Missense_Mutation | rs770791830 | c.709G>A | p.Glu237Lys | p.E237K | P42166 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.448) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
TMPO | deletion | Frame_Shift_Del | c.878_891delNNNNNNNNNNNNNN | p.Thr295SerfsTer7 | p.T295Sfs*7 | protein_coding | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||||
TMPO | insertion | Frame_Shift_Ins | rs770800449 | c.295dupA | p.Thr99AsnfsTer2 | p.T99Nfs*2 | P42166 | protein_coding | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | ||
TMPO | deletion | Frame_Shift_Del | novel | c.674delN | p.Ala226LeufsTer3 | p.A226Lfs*3 | P42167 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
TMPO | SNV | Missense_Mutation | novel | c.764N>A | p.Pro255His | p.P255H | P42166 | protein_coding | deleterious_low_confidence(0) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMPO | SNV | Missense_Mutation | novel | c.1150N>A | p.Leu384Met | p.L384M | P42166 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TMPO | SNV | Missense_Mutation | novel | c.1120N>T | p.Ala374Ser | p.A374S | P42166 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.987) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
TMPO | SNV | Missense_Mutation | c.822C>A | p.Phe274Leu | p.F274L | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |